PRESS RELEASE
MARC COUCKE APPOINTED CHAIRMAN OF MITHRA'S BOARD OF DIRECTORS- Mithra Pharmaceuticals announced today the appointment of Marc Coucke as chairman of the Board of Directors.
- Other changes also occured in the Board of Directors of Mithra Pharmaceuticals.
- Koen Hoffman, CEO of Value Square and former CEO of KBC Securities, was appointed independent director and will become chairman of the audit committee of Mithra.
- Freya Loncin, General Counsel Alychlo, was appointed new non-executive director.
- Professor Jean-Michel Foidart, co-founder of Mithra and current co-chairman of the Scientific Committee of Mithra Pharmaceuticals, was appointed non-executive director.
Other changes for the Board of Directors of Mithra Pharmaceuticals
After the resignation of Barbara De Saedeleer and Marc Foidart and after the death of Jean Sequaris on the 8th July, three new members have been appointed in the Board of Directors of Mithra :
Koen Hoffman, CEO of Value Square and former CEO of KBC Securities, as new independent director and chairman of the audit committee of Mithra.
Freya Loncin, General Counsel Alychlo, as new non-executive director.
Jean-Michel Foidart, co-founder of Mithra and current co-chairman of the scientific committee of Mithra Pharmaceuticals, as non-executive director.
For pictures of François Fornieri, please click here on the following link: http://www.mithra.com/en/logo/
For more information, please contact:Press
Julie Dessart
Chief Communication Officer
+32 4 349 28 22
+32 475 86 41 75
press@mithra.com
Investor Relations
François Fornieri, CEO
+32 4 349 28 22
investorrelations@mithra.com
About MithraMithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. dr. Jean-Michel Foidart, is a pharmaceutical company focused on Women's Health. Mithra's mission is to support and assist women at every stage of their life, thereby improving their overall quality of life. As such the Company aims to become a worldwide leader in women's health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and complex therapeutical entities in four therapeutic fields of women's health, fertility and contraception, menopause and osteoporosis, vaginal infections and cancers.
Mithra has a total headcount of approximately 85 staff members and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com
Important informationThe contents of this announcement include statements that are, or may be deemed to be, "forward- looking statements". These forward-looking statements can be identified by the use of forward- looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are
cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
To subscribe to Mithra's newsletter, visit investors.mithra.com
Mithra Pharmaceuticals SA published this content on 26 August 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 26 August 2016 15:54:08 UTC.
Original documenthttp://investors.mithra.com/wp-content/uploads/2016/08/2016-08-26-CA-modifications-EN.pdf
Public permalinkhttp://www.publicnow.com/view/5DB13D016C788CC44A32D180BBBB3AE76821CFCC